Literature DB >> 11775041

Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors.

S M Stahl1.   

Abstract

Dopamine system stabilizers are a potential new class of antipsychotic agents without motor side effects. All known effective antipsychotics act at D2 receptors. A novel concept for an antipsychotic without motor side effects is to stabilize these receptors rather than block them harshly.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11775041     DOI： 10.4088/jcp.v62n1101

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


  31 in total

1.  Aripiprazole therapy for nicotine dependence.

Authors:  Sriram Ramaswamy; Subhash C Bhatia
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

2.  Atypicality of atypical antipsychotics.

Authors:  Andrew Farah
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

Review 3.  GPCR functional selectivity has therapeutic impact.

Authors:  Richard B Mailman
Journal:  Trends Pharmacol Sci       Date:  2007-07-13       Impact factor: 14.819

4.  Psychotic exacerbation and emotional dampening in the daily life of patients with schizophrenia switched to aripiprazole therapy: a collection of standardized case reports.

Authors:  Johan Lataster; Inez Myin-Germeys; Marieke Wichers; Philippe A E G Delespaul; J van Os; Maarten Bak
Journal:  Ther Adv Psychopharmacol       Date:  2011-10

5.  The dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression.

Authors:  Susanna Waters; Henrik Ponten; Malin Edling; Boel Svanberg; Daniel Klamer; Nicholas Waters
Journal:  J Neural Transm (Vienna)       Date:  2014-05-11       Impact factor: 3.575

Review 6.  Pathophysiology and treatment of psychosis in Parkinson's disease: a review.

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 7.  Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?

Authors:  Richard B Mailman; Vishakantha Murthy
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

8.  Treating bipolar disorder in the primary care setting: the role of aripiprazole.

Authors:  J Sloan Manning; Susan L McElroy
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

Review 9.  Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.

Authors:  Tracy Swainston Harrison; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice.

Authors:  Michel Bourin; Franck Chenu; Corina Prica; Martine Hascoët
Journal:  Psychopharmacology (Berl)       Date:  2009-06-11       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.